Top 10 companies by global revenue from orphan drugs 2028

Forecast of leading 10 pharmaceutical companies by global orphan drug revenue in 2028

Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

March 2023

Region

Worldwide

Survey time period

as of February 2023

Supplementary notes

Products that have orphan and non-orphan drug designations and are expected to generate less than 50% of their sales in 2024 from their orphan-designated indication/s, are excluded from this statistic. This has led to the exclusion of therapies such as Avastin, Opdivo, Enbrel, Herceptin, Humira and Remicade.

Open this statistic in...
Citation formats
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Orphan drugs "

Other statistics that may interest you Orphan drugs

Rare diseases

4

Market overview

5

Companies

4

Products

6

Research and development

6

Further related statistics

20
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Learn more about how Statista can support your business.